If you want blockbuster sales, buy them in
An analysis of recent US drug sales confirms the growing role of licensing and acquisitions, though the biggest sellers conceal some interesting nuance.
Probiodrug wins a market cap-sized grant for Alzheimer’s trial
Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912.
Circassia finds a second way to put investors’ money under threat
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Lundbeck needs deals, but what can it afford?
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
Bayer holds its nerve as patent cliff approaches
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…
Reata gives Abbvie something else to think about
As the final cohort in the Phoenix trial reads out positively for bardoxolone the stage is set for pivotal results and a decision by Abbvie.
Reneuron eyes a partner with new stem cell data
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
German Merck and Glaxo clasp hands in oncology
The €300m deal is in part a high-stakes bid to take on Merck & Co's Keytruda in lung cancer.
Licensing deal activity follows buyout market downwards
Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.